Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Core Viewpoint - Matinas BioPharma Holdings, Inc. has appointed Evelyn D'An as an independent director and Chair of the Audit Committee, effective February 5, 2025, enhancing the board's expertise in financial oversight and corporate governance [1][2]. Company Overview - Matinas BioPharma is a biopharmaceutical company focused on delivering innovative therapies through its lipid nanocrystal (LNC) platform delivery technology [3]. Appointment Details - Evelyn D'An brings extensive experience in corporate governance, financial oversight, and accounting, having served as Chair of Audit Committees for various public and private companies [2]. - D'An is a former partner at Ernst & Young, where she spent 18 years working with clients across multiple sectors, including retail and technology [2]. Leadership Commentary - Jerome D. Jabbour, CEO of Matinas, expressed enthusiasm about D'An's appointment, highlighting her strategic expertise and the value she adds to the board at a critical time for the company [3].